Analysts have raised their price target for Zydus Wellness from ₹489.43 to ₹510.23. This adjustment reflects expectations of stronger revenue growth, even though a lower profit margin is projected.
What's in the News
- Zydus Wellness has incorporated a wholly owned subsidiary, Alidac UK Limited, in the United Kingdom as of August 5, 2025 (Key Developments).
- At the Annual General Meeting on July 30, 2025, shareholders approved changes to the Capital Clause in the company's Memorandum of Association (Key Developments).
- The company declared a dividend of INR 6 per equity share for the financial year ended March 31, 2025, during the AGM on July 30, 2025 (Key Developments).
- A Board Meeting was held on July 30, 2025, to consider and approve the unaudited financial results for the quarter ended June 30, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from ₹489.43 to ₹510.23.
- Revenue Growth forecast has risen significantly, from 10.21% to 33.06%.
- Net Profit Margin is projected to fall from 16.44% to 9.87%.
- Discount Rate remains unchanged at 12.73%.
- Future P/E ratio has decreased slightly, from 36.88x to 36.42x.
Have other thoughts on Zydus Wellness?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.